Peptide vaccines targeting glypican-3 successfully triggered cancer-killing immune responses in most patients across five clinical trials, offering a complement to checkpoint immunotherapy.
Most patients respondedGlypican-3 peptide vaccines induced specific cancer-killing T cells in the majority of patients across five clinical trials
What the researchers found
Glypican-3 peptide vaccines successfully induced cancer-specific cytotoxic T lymphocytes (CTLs) in most patients across multiple clinical trials (five registered trials). The peptide showed extreme cancer specificity when restricted to HLA-A24 and HLA-A2 molecules. The review also found that neoantigen-based personalized immunotherapy shows potential for eliciting cancer regression, and both approaches may complement immune checkpoint inhibitors for patients who don't respond to checkpoint therapy alone.
Why it matters
Immune checkpoint inhibitors have transformed cancer treatment, but many patients don't respond. Peptide vaccines targeting glypican-3 or tumor-specific neoantigens offer complementary strategies that could fill this gap — especially for cancers like hepatocellular carcinoma where glypican-3 is highly expressed.
How the study worked
The authors summarized results from five clinical trials (registered in the UMIN Clinical Trials Registry) testing glypican-3 peptide vaccines in cancer patients. They also reviewed the current state of neoantigen-based personalized cancer immunotherapy, drawing on their own research program and published literature.
Who was studied
Cancer patients across five clinical trials receiving glypican-3 peptide vaccines (HLA-A24 and HLA-A2 restricted)
What this study cannot tell us
The abstract does not provide specific response rates, survival data, or detailed outcomes from the clinical trials mentioned. As a review summarizing the authors' own work, it may present a favorable view of the results. The specific cancer types and patient populations across the five trials are not detailed in the abstract.
How to read the evidence
Based on five registered clinical trials and the authors' direct research experience, this represents moderate clinical evidence. However, the abstract lacks specific outcome data (response rates, survival), and the review nature means results are summarized rather than independently analyzed.
When this study was published
Published in 2018, this review captures an active period of peptide vaccine clinical development. The neoantigen field has advanced significantly since, with several personalized cancer vaccines entering later-stage trials.
The bigger picture
Cancer immunotherapy is moving toward combination strategies. Peptide vaccines like these could be paired with checkpoint inhibitors to boost response rates — the vaccine teaches the immune system what to attack, while the checkpoint inhibitor removes the brakes. The emerging neoantigen approach takes this even further by creating vaccines customized to each patient's specific tumor mutations.
Questions still open
- How effective are glypican-3 peptide vaccines when combined with immune checkpoint inhibitors?
- Can neoantigen-based vaccines be manufactured quickly and cheaply enough for widespread clinical use?
- Which cancer types beyond hepatocellular carcinoma express enough glypican-3 to be targeted by these vaccines?
Common questions
What is glypican-3 and why is it a good cancer vaccine target?
How do peptide cancer vaccines differ from checkpoint inhibitors?
Read the original research
Cancer immunotherapy-targeted glypican-3 or neoantigens.
Cancer science, 109(3), 531-541
Citation
Shimizu, Yasuhiro; Suzuki, Toshihiro; Yoshikawa, Toshiaki; Tsuchiya, Nobuhiro; Sawada, Yu; Endo, Itaru; Nakatsura, Tetsuya. (2018). Cancer immunotherapy-targeted glypican-3 or neoantigens.. Cancer science, 109(3), 531-541. https://doi.org/10.1111/cas.13485